{"id":"https://openalex.org/W4362481247","doi":"https://doi.org/10.1158/1535-7163.22498614","title":"Supplementary Figure 5 from Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models","display_name":"Supplementary Figure 5 from Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362481247","doi":"https://doi.org/10.1158/1535-7163.22498614"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.22498614","doi":"https://doi.org/10.1158/1535-7163.22498614","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22498614","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1535-7163.22498614","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109602285","display_name":"Caroline C. Clark","orcid":"https://orcid.org/0009-0001-3272-2054","observed_orcids":["https://orcid.org/0009-0001-3272-2054"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Caroline C. Clark","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029960276","display_name":"Jeffrey N. Weitzel","orcid":"https://orcid.org/0000-0001-6714-092X","observed_orcids":["https://orcid.org/0000-0001-6714-092X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey N. Weitzel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5035390675","display_name":"Timothy R O'Connor","orcid":"https://orcid.org/0000-0001-5848-3592","observed_orcids":["https://orcid.org/0000-0001-5848-3592"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Timothy R. O'Connor","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/synthetic-lethality","display_name":"synthetic lethality","score":0.9620000123977661},{"id":"https://openalex.org/keywords/veliparib","display_name":"veliparib","score":0.9789999723434448},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9229999780654907},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":1.0},{"id":"https://openalex.org/keywords/brca1","display_name":"BRCA1","score":0.9079999923706055},{"id":"https://openalex.org/keywords/brca2","display_name":"BRCA2","score":1.0},{"id":"https://openalex.org/keywords/rad51-foci","display_name":"RAD51 foci","score":0.9869999885559082},{"id":"https://openalex.org/keywords/dna-repair","display_name":"DNA repair","score":0.6729999780654907},{"id":"https://openalex.org/keywords/isogenic-cell-models","display_name":"isogenic cell models","score":0.7210000157356262},{"id":"https://openalex.org/keywords/hcc1937","display_name":"HCC1937","score":0.9020000100135803},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5929999947547913}],"concepts":[{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.9667354822158813},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.7638498544692993},{"id":"https://openalex.org/C2778502085","wikidata":"https://www.wikidata.org/wiki/Q7662767","display_name":"Synthetic lethality","level":4,"score":0.6150727272033691},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5810033679008484},{"id":"https://openalex.org/C2779012473","wikidata":"https://www.wikidata.org/wiki/Q3235015","display_name":"RAD51","level":4,"score":0.4522264301776886},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4329962134361267},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4302787482738495},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.40321820974349976},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.3916822075843811},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.324851930141449},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.236487478017807},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.23189523816108704},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.15988698601722717},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.10339239239692688},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.09875458478927612},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.06861808896064758},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.05964156985282898},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0517764687538147},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.22498614","doi":"https://doi.org/10.1158/1535-7163.22498614","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22498614","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1535-7163.22498614.v1","doi":"https://doi.org/10.1158/1535-7163.22498614.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22498614.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_5_from_Enhancement_of_Synthetic_Lethality_via_Combinations_of_ABT-888_a_PARP_Inhibitor_and_Carboplatin_i_In_Vitro_i_and_i_In_Vivo_i_Using_BRCA1_and_BRCA2_Isogenic_Models/22498614/1/files/39956985.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22498614","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_5_from_Enhancement_of_Synthetic_Lethality_via_Combinations_of_ABT-888_a_PARP_Inhibitor_and_Carboplatin_i_In_Vitro_i_and_i_In_Vivo_i_Using_BRCA1_and_BRCA2_Isogenic_Models/22498614","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.22498614","doi":"https://doi.org/10.1158/1535-7163.22498614","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22498614","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9391000270843506,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":false},"content_urls":{"pdf":"https://content.openalex.org/works/W4362481247.pdf"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2153798189","https://openalex.org/W7097896784","https://openalex.org/W2038116902","https://openalex.org/W4362478178","https://openalex.org/W7097740881","https://openalex.org/W2522427963","https://openalex.org/W2009231883","https://openalex.org/W6965443026","https://openalex.org/W6908813566","https://openalex.org/W2014421851"],"abstract_inverted_index":{"PDF":[0],"file,":[1],"240K,":[2],"SUPPLEMENTARY":[3],"FIGURE":[4],"S5.":[5],"RAD51":[6,22],"foci":[7,23],"formed":[8],"in":[9],"cells":[10,29],"as":[11],"a":[12],"function":[13],"of":[14],"BRCA":[15],"status":[16],"after":[17,28],"treatment":[18],"with":[19,32,42,55],"ABT-888/carboplatin.":[20],"All":[21],"were":[24,30],"analyzed":[25],"by":[26],"immunostaining":[27],"treated":[31,41,54],"drugs":[33],"for":[34],"24":[35],"h.":[36],"(A)":[37],"HCC1937":[38],"and":[39,52],"HCC1937+BRCA1":[40],"vehicle":[43,56],"or":[44,57],"200":[45],"\u03bcM":[46,48,59,61],"ABT-888/25":[47],"carboplatin.":[49,62],"(B)":[50],"EUFA423":[51],"EUFA423+BRCA2":[53],"12.5":[58],"ABT-888/12.5":[60]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}